Fatty Liver in Inflammatory Bowel Disease (IBD) Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-03-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fatty liver is known to be one of the most frequent liver pathologies in IBD patients (35-40%). Despite this fact, there are only few publications that evaluated the prevalence of fatty liver in IBD patients. Moreover, the pathogenesis of this phenomenon in IBD has not been widely investigated.

The paradox of lean patients and fatty liver can be explained by high use of steroids, by rapid weight loss, and by the abundance of TNFα cytokine in IBD patients that causes insulin resistance.

The aim of the study:

To evaluate the frequency of fatty liver in a cohort of IBD patients and to learn its risk factors.

Methods:

One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will be recruited.

Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.

Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk Factors and Impact MASLD in Patients With IBD

NCT06328452

Metabolic Dysfunction-associated Steatotic Liver Disease

NOT_YET_RECRUITING

Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients

NCT06814600

NAFLD Inflammatory Bowel Diseases Steatosis +1 more

RECRUITING

Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals

NCT04328259

Inflammatory Bowel Disease Patients

UNKNOWN

Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model

NCT07297225

MAFLD Cholecystitis Gallbladder Polyps +1 more

COMPLETED

Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification

NCT01158066

Coronary Artery Calcification

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Disease Fatty Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cases

IBD patients above the age of 18 years old, suffering from the disease for at least one year.

clinical evaluation

Intervention Type OTHER

Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.

Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clinical evaluation

Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.

Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* IBD patients above the age of 18 years old, suffering from the disease for at least one year.

Exclusion Criteria

* Pregnant women,
* Patients suffering from ulcerative colitis after total colectomy,
* HIV patients,
* Patients suffering from other chronic liver disease,
* Patients suffering from cancer currently or in the past, OR
* Patients suffering from any other chronic severe diseases.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No